Sophia Antipolis, France

MEDIAN Technologies at the 2015 ASCO Annual Meeting

MEDIAN will exhibit its solutions for image interpretation and management in oncology trials at ASCO 2015 and will discuss the results of its abstract at Booth #22140, Hall A.

MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology today announced its participation to the 2015 American Society of Clinical Oncology (ASCO) annual meeting, to be held May 29 – June 2, in Chicago, IL, USA (exhibition dates: May 30 – June 1).
During the ASCO annual meeting, the world’s premier oncology conference, MEDIAN will be at Booth #22140, Hall A to give demonstrations of our Lesion Management Solutions software – LMS- proprietary platform. MEDIAN will also present the full range of its services for image interpretation and management in clinical trials and will discuss the results of this study:  Variability in data selection between local sites and blinded independent central review during a RECIST phase II trial: Association with rate of adjudication. (J Clin Oncol 33, 2015 (suppl; abstr e18555).

Download MEDIAN_at_ASCO_2015.pdf

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66